» Articles » PMID: 37545363

An Overview of the Current Debate Between Using Minimally Invasive Surgery Versus Laparotomy for Interval Cytoreductive Surgery in Epithelial Ovarian Cancer

Overview
Journal J Gynecol Oncol
Date 2023 Aug 7
PMID 37545363
Authors
Affiliations
Soon will be listed here.
Abstract

The standard of care for treatment of advanced-stage epithelial ovarian cancer is primarily surgery followed by platinum-based chemotherapy, with the operative goal to achieve complete gross resection. Cytoreductive surgeries for epithelial ovarian cancer historically were performed via open laparotomy; however, as minimally invasive techniques became more widely accepted within gynecologic oncology, interest in employing this approach in the setting of cytoreductive surgery for epithelial ovarian cancer has grown. The purpose of this review was to examine the current debate between the use of minimally invasive surgery versus laparotomy as an approach to interval cytoreductive surgery in advanced epithelial ovarian cancer. While numerous retrospective and feasibility studies have found comparable outcomes with respect to complete gross residual disease, progression-free survival, and overall survival between minimally invasive and laparotomy approaches to interval cytoreductive surgery for epithelial ovarian cancer, methodological challenges limit the utility of these data. Given potential risks of underestimating disease burden and failing to achieve complete resection using a minimally invasive approach, further rigorous studies are needed to evaluate the safety and efficacy of minimally invasive surgery in this setting and to better define the subset of patients who would receive the greatest benefit from a minimally invasive approach.

Citing Articles

A quinoline-2-thione derivative as a novel chemotherapy drug candidate displays anti-tumor activity in vitro and in vivo.

Zhao J, Zhao J, Lin F, Xu L, Chen Z, Jiang Y BMC Cancer. 2024; 24(1):1272.

PMID: 39397012 PMC: 11472586. DOI: 10.1186/s12885-024-13042-7.

References
1.
Filippova O, Boecking K, Broach V, Gardner G, Sonoda Y, Chi D . Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study. Gynecol Oncol. 2024; 187:80-84. DOI: 10.1016/j.ygyno.2024.05.009. View

2.
Chi D, Eisenhauer E, Zivanovic O, Sonoda Y, Abu-Rustum N, Levine D . Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114(1):26-31. DOI: 10.1016/j.ygyno.2009.03.018. View

3.
Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53. DOI: 10.1056/NEJMoa0908806. View

4.
Tang Q, Liu W, Jiang D, Tang J, Zhou Q, Zhang J . Perioperative and Survival Outcomes of Robotic-Assisted Surgery, Comparison with Laparoscopy and Laparotomy, for Ovarian Cancer: A Network Meta-Analysis. J Oncol. 2022; 2022:2084774. PMC: 9078848. DOI: 10.1155/2022/2084774. View

5.
Zivanovic O, Sonoda Y, Diaz J, Levine D, Brown C, Chi D . The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol. 2008; 111(3):431-7. DOI: 10.1016/j.ygyno.2008.08.024. View